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Abstract 
Review on UTS2, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Keywords: UTSII, Urotensin2 
Identity 
Other names: PRO1068, U-II, UCN2, UII 
HGNC (Hugo): UTS2 
Location: 1p36.23 
DNA/RNA 
Description 
The human UTS2 gene is an active cyclic 
heptapeptide and encodes a mature peptide. This 
gene is located on the reverse strand of chromosome 
1. It consists of an open reading frame (ORF) having
372 nucleotides which encodes 124 amino acids. Its 
size is about 14.3 kDa and has an isoelectric point 
7.67. 
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The mature peptide for both transcript variants (TV1 
and TV2) is known to be identical but has different 
amino-terminal end as compared to transcript variant 
1. The two most common transcript variants (TV1 
and TV2) are shown in Figure1. The third transcript 
variant is known to be putative protein coding. It has 
a transcript length of 1601 bps with a translational 
length of 139 residues and has a total of 7 exons with 
6 coding exons. UII is most abundantly expressed in 
the central nervous system, for example in the 
brainstem and spinal cord. Apart from the CNS, UII 
mRNA is also expressed in the liver, kidney, 
cardiomyocytes, coronary and in multiple endocrine 
glands (Ames et al., 1999, Nothacker et al., 1999). 
Pseudogene 
There is no pseudogene for UTS2. 
Protein 
Description 
Urotensin II is known to be a potent vasoactive 
peptide in humans and in several other animal 
models. It is a cyclic peptide of 12 amino acids. The 
cyclic region of the peptide (Cys-Phe-Trp-Lys-Tyr-
Cys) of UII is evolutionary conserved but the N-
terminal region of UII is highly variable (Conlon, 
2000, Conlon, 2008). U-II is known to be the 
endogenous ligand of an orphan G-protein-coupled 
receptor (GPR 14). In humans, UTS2 originated 
from a large precursor molecule i.e prepro-U-II and 
is encoded by a gene on chromosome 1p36. The 
prepro and mature UII peptide sequences are shown 
in Figure2. Two splice variants of the precursor are 
known, one consist of124 amino acids while the 
other has 139 amino acids. Actually human UTS2 
derived from post-translational processing of two 
different precursors, which are alternate splice 
variants (Ames et al., 1999, Coulouarn et al., 1998). 
Ensembl mentions a third transcript variant that is 
known to be putative protein coding. It has a 
translational length of 139 amino acids. UTS2 is 
having a molecular mass of approximately 14.3 kDa 
and has an isoelectric point 7.67. 
The amino acid sequence of UTS2 is highly 
conserved across several vertebrates and shares 
structural similarity to somatostatin. Due to the 
structural similarities between U-II and 
somatostatin, it was wrongly interpreted that UTS2 
shared binding sites with somatostatin. The human 
GPR14 (G-Protein-Coupled Receptor-14) has been 
found out to function as a UTS2 receptor (Ames et 
al., 1999, Liu et al., 1999, Mori et al., 1999, 
Nothacker et al., 1999). It is also known as sensory 
epithelium neuropeptide like receptor (SENR) (Tal 
et al., 1995). This receptor was later called the 
urotensin receptor (UTR) because of the high 
selectivity of GPR 14 for UTS2(Liu et al., 1999). 
The binding of U-II with UTR is functionally 
coupled to calcium mobilization. 
Expression 
UTS2 is widely distributed and is found in a variety 
of different tissues. In humans it has been found in 
the heart (Matsushita et al., 2001), kidney 
(Matsushita et al., 2001, Shenouda et al., 2002, 
Totsune et al., 2003), liver (Totsune et al., 2003, 
Coulouarn et al., 1998) and in the brain and spinal 
cord of several other species. However the 
distribution of UTS2 is somewhat unusual as it is 
found in motor neurons of the spinal cord and motor 
nuclei in the brain (Coulouarn et al., 1998, Dun et al., 
2001). The pre-pro UTS2 has been found to co-
localize with androgen receptors in motor nuclei 
(Pelletier et al., 2002). Immunohistochemistry for 
the UII peptide reveals its presence in the neuronal 
cell soma of the brain and spinal cord (Ames et al., 
1999, Chartrel et al., 1996, Dun et al., 2001). UTS2 
is also shown to be expressed in pancreas (Totsune 
et al., 2003). There is very high expression of UTS2 
proteins in cerebral cortex, hippocampus, lateral 
ventricle and cerebellum of CNS. It is also highly 
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expressed in pancreas, duodenum, small intestine, 
placenta and thyroid gland. UII is moderately 
expressed in gall bladder, stomach, colon, kidney, 
testis, prostate, breast, lung, heart muscle, bronchus. 
It has low expression in skin, soft tissue and bone 
marrow. But it has not been detected in oral mucosa, 
adipose tissue, skeletal muscle and smooth muscle. 
Localisation 
UTS2 has primarily extracellular localisation. This 
protein is found mainly in the human spinal cord 
generally in motoneurons. 
Function 
UTS2 (U-II) is a well known vasoactive hormone 
whose action is mainly dependent on seven 
transmembrane spanning G-protein-coupled 
receptor called GPR14 (Onan et al., 2004). UII play 
an indispensable role in the physiological regulation 
of several organ systems especially within the 
cardiovasculature. It is known to be the most potent 
mammalian vasoconstrictor possessing both 
vasoconstrictor and vasodilatory action properties as 
well as profibrotic and antiapoptotic activity 
(Langham & Kelly, 2013).  
UTS2 possesses several cardiovascular actions such 
as potent vasoactive and cardiac inotropic and 
hypertropic properties (Douglas et al., 2002). It 
activates the G protein-coupled receptor UTS2R and 
thus exerts various cardiovascular effects and has a 
role in the pathophysiology of atherosclerosis 
(Segain et al., 2007).  
It negatively regulates blood pressure. U-II is 
supposed to have several behavioral activities as it 
occurs in the central nervous system and is widely 
distributed in the brain.  
It has been shown in studies conducted in rodents 
that central administration of U-II stimulates 
locomotion, stimulates anxiety and depressive-like 
conditions, provokes feeding activity and increases 
the duration of paradoxical sleep episodes (do Rego 
et al., 2008). UII also exerts a wide range of actions 
in other systems, such as proliferation of vascular 
smooth muscle cells, fibroblasts, and cancer cells 
(Wu et al., 2010, Lin et al., 2004, Ross et al., 2010). 
In addition it also increases foam cell formation, 
chemotaxis of inflammatory cells, and inotropic and 
hypertrophic effects on heart muscle, inhibits insulin 
release (Saez et al., 2011), modulates glomerular 
filtration (Langham & Kelly, 2013) and release of 
catecholamines and may help in the regulation of 
food intake and the sleep cycle (Huitron-Resendiz et 
al., 2005).  
Guidolin et al. stated that urotensin-II has an 
angiogenic role (Guidolin et al., 2010). Furthermore 
endogenous urotensin II has a role in erectile 
functioning by selectively modulating its mechanism 
through eNOS (Bianca et al., 2012). 
Homology 
UTS2 is a partial homologue of somatostatin and 
shares structural similarity to somatostatin. It was 
also demonstrated that both rat and mouse homologs 
share sequence homology with human prepro UTS2 
(Coulouarn et al., 1999). All the known homologs of 
UTS2 are known to share a highly conserved cyclic 
region in the peptide which predicts that this region 
has a functional significance. 
Mutations 
Different genetic polymorphisms in UTS2 and 
their association with diseases:  
Several single nucleotide polymorphisms (SNPs) in 
genes encoding for urotensin II (UTS2) are known 
and have been well studied. According to the US 
National Center for Biotechnology Information 
(NCBI) database, over 60 single nucleotide 
polymorphisms (SNP) have been noted in the human 
UTS2 gene. Three of these SNP show amino acid 
changes in the UTS2 gene sequence. The well 
known SNP, 143G>A (T21M, rs228648) in the 
UTS2 gene is found to be associated with type 2 
diabetes in Han people residing in northern China 
(Suguro et al., 2007, Zhu et al., 2002) while the other 
SNP, 3836C>T (S89N, rs2890565) has association 
with higher plasma insulin level, insulin resistance, 
and susceptibility of developing type 2 diabetes in 
Hong Kong Chinese and Japanese (Ong et al., 2006, 
Suzuki et al., 2004, Wenyi et al., 2003). The SNP, 
3836C>T is supposed to be a functional SNP as it 
has association with higher plasma UTS2 level (Ong 
et al., 2006). Recently it has been found that 
Thr21Met (T21M) polymorphisms of the UTS2 gene 
were associated with higher risk of developing 
Behcet's disease as well as Systemic Sclerosis 
(Oztuzcu et al., 2013, Pehlivan et al., 2012). Both 
Thr21Met (T21M) and Ser89Asn (S89N) 
polymorphisms of the UTS2 gene have been found 
to be pathologically associated with the risk of 
developing diabetes and Diabetic Retinopathy 
(Okumus et al., 2012). The exchange of serine 
instead of asparagine at amino acid position 89 
changes the structure of UTS2. Due to this, mutation 
at this particular point is likely to form immature UII 
peptide that might cause several pathological 
conditions (Okumus et al., 2012). 
Implicated in 
Breast cancer 
In a recent study, Balakan et al. (2014) found that U-
II and UTR mRNA is being expressed in the  
breast tissue and breast cancer tissue.  Consequently 
they found an association of UTS2 with menopausal 
status, and extra-nodal and lymphatic invasion in 
breast cancer patients (Balakan et al., 2014). 
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Atherosclerosis 
Atherosclerosis is vascular inflammation which is 
chronic in nature and results in the deposition of lipid 
and leucocyte in the arterial wall (Loirand et al., 
2008). In hypertensive patients, plasma U-II level is 
found to be positively correlated with carotid 
atherosclerosis (Suguro et al., 2007) as well as in 
patients with coronary artery isease (Heringlake et 
al., 2004) 
Metabolic syndrome 
UTS2 is considered to give rise to the metabolic 
syndrome and its components, like hyperglycemia, 
hypertension, insulin resistance and inflammation. It 
has a role in inflammation by effecting ingestive 
behavior. Plasma UTS2 level has a positive 
correlation with systolic blood pressure and insulin 
resistance (Cheung et al., 2004, Ong et al., 2006, 
Suguro et al., 2007). The two well known disorders 
i.e hypertension and insulin resistance are known to 
occur together as components of the metabolic 
syndrome ( Reaven G.M, 1988). 
Behcet's disease 
Oztuzcu et al. (2013) described that Thr21Met 
(T21M) polymorphisms of the UTS2 gene is known 
to be associated with Behcet's disease (BD) in 
Turkish population (Oztuzcu et al., 2013). 
Diabetes Mellitus and Diabetic 
Retinopathy 
An association between Thr21Met and Ser89Asn 
polymorphisms of the UTS2 gene, Diabetes Mellitus 
and Diabetic Retinopathy has been found by 
Okumus et al. (Okumus et al., 2012). 
Systemic Sclerosis 
Pehlivan et al. (2011) suggested that Thr21Met, but 
not Ser89Asn has an important role in the 
development of Systemic Sclerosis, and a powerful 
indicator of severe skin and lung involvement in 
patients with Systemic Sclerosis (Pehlivan et al., 
2012). 
Renal disease 
Totsune et al. (2001) reported higher levels of 
plasma UTS2 i.e an increase in three fold and two 
fold in patients with renal dysfunction, with and 
without dialysis respectively as compared with 
healthy control (Totsune et al., 2001). This indicated 
a role of UTS2 in renal function. 
Congestive Heart Failure 
It has been found that myocardial UII is significantly 
expressed in heart samples taken from patients with 
congestive heart failure as compared to controls, 
which was inversely correlated with ejection fraction 
(Douglas et al., 2002). 
Type 2 diabetes mellitus 
Wenyi et al. reported the association of S89N 
polymorphism in the UTS2 with the development of 
Type 2 diabetes, via insulin sensitivity, in Japanese 
subjects (Wenyi et al., 2003). 
Pre-eclampsia. 
ElSharkawy et al. showed the elevation of UTS2 in 
the serum of PE patients which could be correlated 
to the severity and/or progression of the disease. The 
UTS2 genotype frequencies between patients and 
control groups showed a significant difference, 
which implies a potential benefit for UTS2 gene or 
level in serum as a diagnostic or prognostic indicator 
in pre-eclampsia (ElSharkawy et al., 2014). 
Endothelial nitric oxide synthase (eNOS) 
(Glu298Asp) and UTS2 (UTS2 S89N) gene 
polymorphisms are promising markers for early 
prediction of preeclampsia in Egyptian females (El-
Sherbiny et al., 2013). 
Schizophrenia 
Higher UTS2 expression was found in schizophrenia 
patients suggesting that UTS2 level may be a 
probable candidate related to the pathology of the 
disease (Bulbul et al., 2014). 
To be noted 
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